Ohio’s Attorney General Suing Drug Manufacturers
On Wednesday the Attorney General for the state of Ohio, Mike DeWine, filed a suit against five major drug manufacturers
Read More
Part D/Prescription Drugs
Mylan may have overcharged taxpayers by $1.27 billion for EpiPens, HHS says
(By Ike Swetlitz for STAT) Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its signature
Read MoreDrug Rebates Reward Industry Players — And Often Hurt Patients
(By Sarah Jane Tribble for Kaiser Health News) Medicare and its beneficiaries aren’t the winners in the behind-the-scenes rebate game
Read MoreOptum, Merck to collaborate on value-based reimbursement models for prescription drugs
(By Morgan Haefner for Becker’s Hospital Review) Eden Prairie, Minn.-based Optum, the health services platform of Minnetonka, Minn.-based UnitedHealth Group, entered a
Read MoreAppealing Drug Cost Transparency in Little Rock
The Pharmaceutical Care Management Association of Washington, representing the largest PBMs in the country, is appealing the March 1 decision
Read MoreFDA Commissioner Plans on Stopping Pharma from Price Gouging
On Thursday the FDA commissioner Scott Gottlieb testified before the House appropriations subcommittee on several methods that could prevent biopharma
Read MoreWill Competition and Innovation Lower Drug Prices?
Grace-Marie Turner, President of Galen Institute, writes in the Forbes’ contributor column why federal taxes will not bring down drug
Read MoreThe Creation of Average Sales Price in Medicare Part B Outpatient Prescription Drugs
When Medicare Modernization Act (MMA) was first implemented much of the discussion was centered about creation of Medicare Part D;
Read MoreNOT GETTING QUALITY CARE? LET US (Medicare) KNOW
(Source – blog.Medicare.gov) Did you know that if you’re unhappy with your medical care, there are ways to let us
Read MoreNew York State Wants Its Prescription Drug Money Back — Or Else
(By Julie Appleby for Kaiser Health News) New York Medicaid regulators aim to use the threat of imposing increased scrutiny of
Read More